| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |

* From the Department of Anesthesia and Pediatrics, Maisonneuve-Rosemont Hospital; and
The Research Center, Ste-Justine Hospital, University of Montreal, Montreal, Quebec, Canada.
Address correspondence to: Dr. Joanne Guay, Department of Anesthesia, Maisonneuve-Rosemont Hospital, 5415 lAssomption Boulevard, Montreal, Quebec H1T 2M4, Canada. Phone: 514-252-3426, Fax: 514-252-3542; E-mail: joanne.guay{at}umontreal.ca
| Abstract |
|---|
|
|
|---|
Methods: Charts from all patients for whom a cardiorespiratory arrest code was called during a six-year period in a university affiliated centre were reviewed. Data were recorded according to the pediatric Utstein guidelines and a P < 0.05 was considered significant.
Results: Of the 234 calls, 203 were retained for analysis. The overall survival rate at one year was 26.0% of which 10% had deterioration of their neurologic status compared to the pre-cardiorespiratory arrest evaluation. Time to achieve sustained return of spontaneous circulation (ROSC; P < 0.0001) and sustained measurable blood pressure (P = 0.002), to perform endotracheal intubation (P = 0.04) and the dose of sodium bicarbonate (P < 0.0001) were indicators of long-term survival. Two patients were alive at one year with unchanged neurologic status despite a time to achieve sustained ROSC longer than 30 min (38 and 44 min). The mean first epinephrine dose of patients for whom ROSC was achieved but unsustained was higher than those for whom ROSC was achieved and sustained (0.038 ± 0.069 mgkg1 vs 0.011 ± 0.006 mgkg1; P = 0.004). Survival rate and mean first epinephrine dose of patients who received their first epinephrine dose endotracheally (13.3%; 0.011 ± 0.004 mgkg1) were comparable to those of patients who received their first epinephrine dose intravenously (7%; 0.015 ± 0.027 mgkg1).
Conclusions: For intravenously administered epinephrine, a dose of 0.01 mgkg1 seems appropriate as the first dose. The endotracheal route is a valuable alternative for epinephrine administration and, for infants, the dose does not need to be increased. A minimal resuscitation duration time of 30 min can be misleading if ROSC is used as the indicator.
| Introduction |
|---|
|
|
|---|
Epinephrine remains the most useful and widely used drug in pediatric cardiorespiratory arrest. It improves cerebral and coronary blood flow, a critical determinant for return of spontaneous pulse, and is the first line drug for treatment of bradycardia with poor perfusion and asystole, the two most common initial rhythms observed in in-hospital pediatric cardiorespiratory arrests.4,5 However, despite its widespread use, there are actually few available human data on the optimal dose of epinephrine that should be administered during pediatric cardiorespiratory resuscitation (CPR). Three studies, two retrospective and one prospective, have compared what are actually considered standard doses for iv epinephrine (0.01 or 0.02 mgkg1) to "high" epinephrine doses (0.1 or 0.2 mgkg1) with contradictory results.68 The possible efficacy of lower or intermediate doses has not been evaluated so far.
The aims of this study were to report data from a six-year experience of in-hospital pediatric CPR in a tertiary care centre according to the pediatric Utstein style and to evaluate the influence of advanced life support (ALS) interventions including various dosages of epinephrine on survival and functional outcome after pediatric CPR.
| Methods |
|---|
|
|
|---|
With institutional Review Board approval, all charts of patients for whom a cardiorespiratory arrest code had been called between January 1 1983 to December 31 1987 were reviewed by one of the two investigators. We abstracted data on patient demographics and details on the cardiorespiratory arrest (Table A, available as Additional Material at www.cja-jca.org). We classified the etiology of the arrest by the system involved (cardiac and / or respiratory) and by the disease. Since there is a difference in severity between respiratory and cardiac arrests, we first classified each arrest as respiratory, cardiac, or cardiorespiratory. To provide a more detailed picture of the etiology for future allocation of educational resources and monies, we then classified each arrest by the etiological factor that preceded the respiratory and/or cardiac compromise.
From the abstracted data, a pediatric cerebral performance category (PCPC) score, from 1 to 6, was attributed before cardiac arrest and at 24 hr, seven, 30, and 365 days post-arrest, and at discharge from hospital. When data were not available from the chart, the requisite information was sought via a telephone interview with the childs parents or the childs primary physician. The PCPC score is a six-point score describing neurological and cognitive disability and function (Table B, available as Additional Material at www.cja-jca.org).2 The difference between the pre-arrest score and the hospital discharge or one-year score was calculated for each patient (i.e., pre-arrest PCPC - discharge or one-year PCPC). When a negative difference was observed, the reason for the increased disability or lower function was classified as secondary to the illness or injury that led to the arrest, secondary to the arrest or resuscitation, or unrelated to the index arrest. When a patient suffered from more than one cardiorespiratory arrest within a year, only the first event was studied and the patient was considered dead (PCPC = 6) from the date of the second event.
Data were analyzed using the JMP 5.01 software (SAS Institute Inc. 2002, Cary, NC, USA). Nominal and ordinal data were analyzed with survival analysis, likelihood ratio tests, and nominal logistic regression. Continuous variables were described using mean ± standard deviation and were analyzed with linear and stepwise regressions. Epinephrine dosages among the different ROSC groups (ROSC never achieved, ROSC achieved but unsustained, and ROSC achieved and sustained for 20 min or longer) were compared using ANOVA. A P-value of less than 0.05 was considered to be statistically significant.
| Results |
|---|
|
|
|---|
|
|
|
Factors that were associated with one-year survival (P < 0.25) were the need for at least one dose of epinephrine (P = 0.002), type of cardiorespiratory arrest (P = 0.09), initial rhythm (P = 0.12), pre-existing chronic disease (P = 0.21), and the time required to perform endotracheal intubation (P = 0.21).
Two patients had a one-year survival without neurological deterioration despite requiring 38 and 44 min respectively to achieve a sustained ROSC. One of these patients also required 34 min to achieve a sustained measurable blood pressure.
The first epinephrine dose varied from 0.0004 to 0.24 mgkg1 (n = 97). The mean first dose was 0.013 ± 0.009 mgkg1 for patients for whom a ROSC was never achieved, 0.038 ± 0.069 mgkg1 for those for whom a ROSC was achieved but unsustained, and 0.011 ± 0.006 mgkg1 for those for whom a sustained ROSC was achieved (P = 0.004). For patients with bradycardia as initial rhythm the first dose of epinephrine was 0.014 ± 0.013 mgkg1 for patients for whom a ROSC was never achieved, 0.055 ± 0.085 mgkg1 for those for whom a ROSC was achieved but unsustained, and 0.011 ± 0.005 mgkg1 for those for whom a sustained ROSC was achieved (P = 0.01). For patients who received epinephrine, there was no immediate survivor (ROSC sustained for 20 min or higher) if the first dose of epinephrine was lower than 0.0018 mgkg1 or higher than 0.0357 mgkg1 and there was no 24 hr survival if the first dose of epinephrine was lower than 0.0018 mgkg1 or higher than 0.019 mgkg1. The total dose of epinephrine was 0.096 ± 0.21 mgkg1 for patients for whom a ROSC was never achieved, 0.15 ± 0.157 mgkg1 for patients for whom a ROSC was achieved but unsustained, and 0.032 ± 0.047 for those in whom a sustained ROSC was achieved (P = 0.007). The mean epinephrine dose of patients who received their first epinephrine dose intravenously was 0.015 ± 0.027 mgkg1 (n = 86) and their survival rate was 7%. The mean epinephrine dose of patients who received their first epinephrine dose through their endotracheal tube was 0.011 ± 0.004 mgkg1 and their survival rate was 13.3% (n = 15). The mean age of patients who received their first epinephrine dose endotracheally was 2.30 ± 4.56 yr (median 0.58 yr; 25 and 75% quartiles 0.33 and one year).
| Discussion |
|---|
|
|
|---|
In the present study, the time from initiation of CPR to intubation of the trachea was an important factor for long-term survival (P = 0.04). For patients requiring endotracheal intubation, none survived long-term when the trachea was intubated 20 min or later during CPR. These results suggest that early endotracheal intubation by a well trained resuscitator should probably be recommended for all these patients.
Vascular access is often difficult to achieve in small children. To obviate this problem, intraosseous cannulation has been recommended. In the present study, time to obtain vascular access did not correlate significantly with long-term survival (n = 25). When the first dose of epinephrine was administered endotracheally, the survival rate was equivalent to that of patients receiving their first dose of epinephrine intravenously (13.3% vs 7%). These results suggest that the endotracheal route is a valuable alternative for the first dose of epinephrine during pediatric resuscitation and that it should be used while iv or intraosseous access is sought. In adults, it has been suggested that, during resuscitation, drugs administered through central venous access would be more effective than peripherally administered drugs. In the present study, the long-term survival rate was not better in patients for whom central venous access was present (13.5% for all sites) than for those in whom only a peripheral access was available (29.2%), suggesting that a patent peripheral vein can be as effective as a central vein in pediatric CPR (Table II
). However, these results should be interpreted cautiously since many of our patients with in situ femoral or internal jugular venous access before their arrests were patients hospitalized in the pediatric intensive care unit after an operation for a cardiac congenital defect and the long-term survival rate of these patients was poor (13.3%; Table I
).
In its most recent publication, the AHA recommends that the first dose of intravenously administered epinephrine should be 0.01 mgkg1 followed by the same dose or a dose of 0.1 mgkg1 in the absence of an adequate response to the first dose after three to five minutes.9 Our results suggest that the recommendation for the first dose of intravenously administered epinephrine is appropriate since the mean dose of patients in whom a sustained ROSC was achieved was 0.011 ± 0.006 mgkg1 compared to 0.038 ± 0.069 mgkg1 for those in whom a ROSC was achieved but unsustained (P = 0.004). Our results indirectly suggest that a higher initial dose might be dangerous since the mean dose of patients in whom a ROSC was achieved but unsustained was significantly higher (all patients and subgroup of patients with bradycardia as initial rhythm).
For endotracheally administered epinephrine, current recommendations suggest an initial dose of 0.1 mgkg1. In the present study, the mean dose of patients who received their first epinephrine dose intratracheally was 0.011 ± 0.004 mgkg1 and their survival rate (13.3%, n = 15) was comparable to those who received their first epinephrine dose intravenously (7%, n = 86). These results suggest that in infants, increasing the first dose of epinephrine when it has to be administered endotracheally might not be necessary.
In a retrospective study on 20 near-drowning pediatric patients, Ashwal et al. reported that an elevated initial blood glucose was highly predictive of those patients who died (mean 28.4 ± 6.1 mmolL1) or remained in a vegetative state (25.8 ± 5.8 mmolL1) compared with those who recovered completely (13.2 ± 9.4 mmolL1).10 Despite a higher number of observations and a wide range of blood glucose levels, we did not find a correlation between either pre- or post-arrest blood glucose levels and survival or neurological prognosis. However, this does not imply that hyperglycemia should not be appropriately treated but that high blood glucose levels measured before or after a cardiorespiratory arrest should not be taken as a predictor of poor prognosis and used as an argument to withhold subsequent ALS interventions in children.
In the past, the definition of resuscitation was not always the same from one study to another; thus, it was difficult to determine what should be an appropriate duration of resuscitative efforts before declaring a patient dead. In adults, the interval time between collapse and achievement of a ROSC is a powerful indicator of ultimate survival and the Pediatric Utstein Symposium proposed its use in children. In a way, our results are in agreement with this recommendation since there was a good correlation between time to establish a sustained ROSC and survival (P < 0.0001). However, if this definition had been used and resuscitative effort had been terminated after 30 min, two of our intact survivors would have died. Time to achieve return of a sustained spontaneous ventilation is not very useful in this population, since sedatives and/or neuromuscular blocking agents are often used after resuscitation and, indeed, did not correlate with long-term survival in our patients. In the present study, return of a measurable blood pressure was also an indicator of long-term survival (P = 0.002).
The longest time to achieve a sustained measurable blood pressure that was associated with intact survival at one year was 34 min. Thus, absence of return of a sustained measurable blood pressure within 40 min might be an alternative to help determine the optimal minimum duration of CPR in children. Further studies will be needed to solve this issue.
In conclusion, the pediatric Utstein guidelines proved to be a valuable and easy to use tool to evaluate the efficacy of ALS interventions in pediatric in-hospital cardiorespiratory arrests. When an endotracheal tube is needed, its insertion should be done within 20 min by a trained resuscitator. For intravenously administered epinephrine, a dose of 0.01 mgkg1 seems appropriate as the first dose. The endotracheal route is a valuable alternative while waiting for iv or intraosseous access. For infants (less than one year of age), a dose of 0.01 mgkg1 administered via the endotracheal route seems as effective as the same dose administered via the iv route. Finally although the time to achieve a ROSC is an indicator of long-term survival in pediatric CPR, it could be misleading if a limit of 30 min is chosen to determine the minimum acceptable duration of resuscitation before termination of resuscitative efforts.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
2 Zaritsky A, Nadkarni V, Hazinski MF, et al. Special report: AHA medical/scientific statement. Recommended guidelines for uniform reporting of pediatric advanced life support: the Pediatric Utstein Style. Resuscitation 1995; 30: 95115.[Medline]
3 Cummins RO, Chamberlain D, Hazinski MF, et al. Recommended guidelines for reviewing, reporting, and conducting research on in-hospital resuscitation: the in-hospital Utstein style. Resuscitation 1997; 34: 15183.[Medline]
4 Niemann JT, Criley JM, Rosborough JP, Niskanen RA, Alferness C. Predictive indices of successful cardiac resuscitation after prolonged arrest and experimental cardiopulmonary resuscitation. Ann Emerg Med 1985; 14: 5218.[Medline]
5 Sanders AB, Ewy GA, Taft TV. Prognostic and therapeutic importance of the aortic diastolic pressure in resuscitation from cardiac arrest. Crit Care Med 1984; 12: 8713.[Medline]
6 Goetting MG, Paradis NA. High-dose epinephrine improves outcome from pediatric cardiac arrest. Ann Emerg Med 1991; 20: 226.[Medline]
7 Carpenter TC, Stenmark KR. High-dose epinephrine is not superior to standard-dose epinephrine in pediatric in-hospital cardiopulmonary arrest. Pediatrics 1997; 99: 4038.
8 Dieckmann RA, Vardis R. High-dose epinephrine in pediatric out-of-hospital cardiopulmonary arrest. Pediatrics 1995; 95: 90113.
9 Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. International consensus on science. Part 10: Pediatric advanced life support. The American Heart Association in collaboration with the International liaison committee on resuscitation (ILCOR). Circulation 2000; 102(suppl I): I-291342.[Medline]
10 Ashwal S, Schneider S, Tomasi L, Thompson J. Prognostic implications of hyperglycemia and reduced cerebral blood flow in childhood near-drowning. Neurology 1990; 40: 8203.
This article has been cited by other articles:
![]() |
P Jones and N Lode Ventricular fibrillation and defibrillation Arch. Dis. Child., October 1, 2007; 92(10): 916 - 921. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Guay, P. de Moerloose, and D. Lasne Minimizing perioperative blood loss and transfusions in children: [Reduire les pertes sanguines et les besoins transfusionnels en chirurgie pediatrique]. Can J Anesth, June 1, 2006; 53(6_suppl): S59 - S67. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |